SQI Diagnostics Reports Third Quarter 2022 Results

Rhea-AI Summary

SQI Diagnostics Inc. (TSXV: SQD, OTCQB: SQIDF) reported a significant revenue increase for Q3 2022, reaching $1.2M, up from $0.3M in Q3 2021. This growth is primarily due to the acquisition of a COVID-19 testing distribution business. However, SG&A expenses remained constant at $1.5M, influenced by previous credits in Q3 2021. The company's net working capital deficit was $(4.4M) as of June 30, 2022, resulting from a short-term credit facility used for the acquisition. Cash and cash equivalents stood at $4.0M.

Positive

• Revenue rose to $1.2M in Q3 2022, significantly higher than $0.3M in Q3 2021, attributed to COVID-19 testing distribution.
• Gross profit increased to $0.4M in Q3 2022, driven by the COVID-19 human testing distribution business.

Negative

• Net working capital deficit of $(4.4M) as of June 30, 2022, compared to $0.7M on September 30, 2021.
• SG&A expenses were $1.5M, unchanged due to prior year credits, indicating ongoing high operational costs.

New Business Contributes $1.1M in Revenue

TORONTO, Aug. 29, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the third quarter for fiscal year ending September 30, 2022.

"This quarter saw another healthy revenue improvement year-over-year as customers continued to engage in PCR testing using Biomeme's mobile test which currently detects all variants of COVID-19. We are cautiously optimistic that COVID-19 testing will continue into the fall months and have secured the distribution rights for Quidel's Sofia 2 Flu + SARS Antigen Fluorescent Immunoassay (FIA) product which is capable of testing for both Influenza A virus (Flu A) and Influenza B virus (Flu B) as well as COVID-19 on a single test cartridge" said Andrew Morris, President and CEO of SQI Diagnostics.

Q3 2022 Financial Highlights

• Sales of $1.2M in Q3 2022 were significantly higher, compared to $0.3M in Q3 2021. The increase in sales is attributed to the COVID-19 human testing distribution business acquired during the second quarter of fiscal 2022.
• Gross profit was $.4M in Q3 2022, compared to $0.3M in Q3 2021 driven by the COVID-19 human testing distribution business.
• SG&A expense was $1.5M in Q3 2022, compared to ($1.5M) in Q3 2021. The difference in SG&A expense is mainly related to a Q3 2021 credit of $2.5M due to the reversal of stock option expense recognized previously for the former CEO and the partial recovery of approximately $0.4M that had been previously written-off. SG&A expenses were also impacted year-over-year due to higher professional fees of $0.4M, higher administration costs of $0.5M and higher salaries and wages of $0.4M owing to a severance payment in Q3 2021 for the previous CEO.
• The R&D expense category, which includes Manufacturing, Quality and Engineering was $1.7M in Q3 2022, compared to $1.9M in Q3 2021. R&D expense decreased year-over-year mainly due to $.5M lower spend in laboratory costs and supplies primarily due to lower consulting costs Additionally, in Q3 2021, the Company was eligible to claim the Canada Emergency Wage Subsidy, the absence of which has eliminated the offset to costs in the current quarter. These higher costs were offset by approximately $0.5M lower spend in laboratory costs and supplies.
• Cash and cash equivalents were $4.0M as of June 30, 2022.
• Net working capital was $(4.4M) as of June 30, 2022, compared to $0.7M on September 30, 2021; the working capital deficit is due to the $7.5M short term credit facility used to acquire the COVID-19 PCR business.

Q3 2022 Corporate Highlights

• During the quarter, the Company issued secured debenture purchased by insiders of the Company with a principal amount of $4,050,000 which bears an interest rate of 8% and will mature in 2 years from the date of issuance.
• The Company also extended the maturity date of the $7,500,000 Credit Facility entered with Pivot Financial & the Insider Lenders in Q2 2022 to October 28, 2022.

About SQI Diagnostics

SQI Diagnostics is a leader in the science of lung health. The Company develops and manufactures respiratory health and precision medicine tests that run on SQI's fully automated systems. The Company's tests simplify and improve COVID-19 antibody monitoring, Rapid Acute Lung Injury testing, donor organ transplant informatics, and immunological protein and antibody testing. SQI Diagnostics is driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives. For more information, please visit www.sqidiagnostics.com.

Contact:

Chief Financial Officer
Morlan Reddock
437-235-6563
mreddock@sqidiagnostics.com

FORWARD-LOOKING INFORMATION

This press release contains certain words and statements, which may constitute "forward-looking statements" within the meaning of applicable securities laws relating to future events or future performance and reflect the current expectations and assumptions of the Company regarding its growth, results of operations, performance, business prospects and opportunities. These statements generally can be identified by use of forward-looking words such as "may", "would", "could", "will", "should", "expect", "plan", "estimate", "anticipate", "intends", "believe", "potential", or "continue" or the negative thereof or similar variations. The Company's actual results and performance discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, the effect of the global pandemic and consequent economic disruption, and the factors detailed in the Company's ongoing filings with the securities regulatory authorities, available at www.sedar.com. Although the forward-looking statements contained herein are based on what we consider to be reasonable assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward looking statements, and our assumptions may prove to be incorrect. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sqi-diagnostics-reports-third-quarter-2022-results-301613637.html

SOURCE SQI Diagnostics Inc.

FAQ

What were SQI Diagnostics' financial results for Q3 2022?

SQI Diagnostics reported $1.2M in revenue for Q3 2022, up from $0.3M in Q3 2021, and a gross profit of $0.4M.

How did the acquisition impact SQI Diagnostics' revenue?

The acquisition of the COVID-19 testing distribution business significantly contributed to the revenue increase in Q3 2022.

What is the current cash position of SQI Diagnostics?

As of June 30, 2022, SQI Diagnostics had cash and cash equivalents of $4.0M.

What is the net working capital position for SQI Diagnostics as of June 30, 2022?

The net working capital deficit for SQI Diagnostics was $(4.4M) as of June 30, 2022.

What is the significance of SG&A expenses in SQI Diagnostics' Q3 2022 results?

SG&A expenses were $1.5M in Q3 2022, unchanged from the previous year, indicating sustained operational costs despite revenue growth.